Overview
Founded in Ghent in 2020 as a spin-off from VIB, UGent, and VUB, Animab is developing a proprietary platform for delivering monoclonal antibodies orally to livestock. Conventional antibody therapies require injection, which is impractical at agricultural scale. Animab's technology enables therapeutic proteins to survive the digestive tract and reach systemic circulation, opening a new administration route for biologics in veterinary medicine.
The company raised EUR 10M in a Series B round in July 2025, bringing total funding to EUR 25.4M. The round supports continued clinical development of lead programs targeting major infectious diseases in poultry and pigs.
Animab operates within the dense Ghent biotech and agri-innovation cluster, benefiting from proximity to UGent's veterinary and life sciences research capabilities.
Funding & milestones
1 events found for Animab · 2025
Series BVenture / equityDetailsEUR 10M
Reported amount EUR 10,000,000
Source not attached to this recordDeal record
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Profile narrative
- Series B, EUR 10M, Jul 2025
- Total raised: EUR 25.4M
Key people
Backers
QBIC
Belgian inter-university deep-tech fund backed by UGent, VUB, UAntwerp, UHasselt, ULiege, VITO, imec, and partner hospitals.
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.